key: cord-0788365-1x8pru5j
authors: Natarajan, S.; Anbarasi, C.; Sathiyarajeswaran, P.; Manickam, P.; Geetha, S.; Kathiravan, R.; Prathiba, P.; Pitchiahkumar, M.; Parthiban, P.; Kanakavalli, K.; Balaji, P.
title: The efficacy of Siddha Medicine, Kabasura Kudineer (KSK) compared to Vitamin C & Zinc (CZ) supplementation in the management of asymptomatic COVID-19 cases: A structured summary of a study protocol for a randomised controlled trial
date: 2020-10-27
journal: Trials
DOI: 10.1186/s13063-020-04823-z
sha: 56a32a6a88c8588f0e2d7e9ce914f2a272709789
doc_id: 788365
cord_uid: 1x8pru5j

OBJECTIVES: The primary objectives of this study are to determine efficacy of Siddha medicine, Kabasura kudineer in reduction of SARS-CoV-2 viral load and reducing the onset of symptoms in asymptomatic COVID-19 when compared to Vitamin C and Zinc (CZ) supplementation. In addition, the trial will examine the changes in the immunological markers of the Siddha medicine against control. The secondary objectives of the trial are to evaluate the safety of the Siddha medicine and to document clinical profile of asymptomatic COVID-19 as per principles of Siddha system of Medicine. TRIAL DESIGN: A single centre, open-label, parallel group (1:1 allocation ratio), exploratory randomized controlled trial. PARTICIPANTS: Cases admitted at non-hospital settings designated as COVID Care Centre and managed by the State Government Stanley Medical College, Chennai, Tamil Nadu, India will be recruited. Eligible participants will be those tested positive for COVID-19 by Reverse Transcriptase Polymerase Chain reaction (RT-PCR) aged 18 to 55 years without any symptoms and co-morbidities like diabetes mellitus, hypertension and bronchial asthma. Those pregnant or lactating, with severe respiratory disease, already participating in COVID trials and with severe illness like malignancy will be excluded. INTERVENTION AND COMPARATOR: Adopting traditional methods, decoction of Kabasura kudineer will be prepared by boiling 5g of KSK powder in 240 ml water and reduced to one-fourth (60ml) and filtered. The KSK group will receive a dose of 60ml decoction, orally in the morning and evening after food for 14 days. The control group will receive Vitamin C (60000 IU) and Zinc tablets (100mg) orally in the morning and evening respectively for 14 days. MAIN OUTCOMES: The primary outcomes are the reduction in the SARS-CoV-2 load [as measured by cyclic threshold (CT) value of RT-PCR] from the baseline to that of seventh day of the treatment, prevention of progression of asymptomatic to symptomatic state (clinical symptoms like fever, cough and breathlessness) and changes in the immunity markers [Interleukins (IL) 6, IL10, IL2, Interferon gamma (IFNγ) and Tumor Necrosis Factor (TNF) alpha]. Clinical assessment of COVID-19 as per standard Siddha system of medicine principles and the occurrence of adverse effects will be documented as secondary outcomes. RANDOMISATION: The assignment to the study or control group will be allocated in equal numbers through randomization using random number generation in Microsoft Excel by a statistician who is not involved in the trial. The allocation scheme will be made by an independent statistician using a sealed envelope. The participants will be allocated immediately after the eligibility assessment and informed consent procedures. BLINDING (MASKING): This study is unblinded. The investigators will be blinded to data analysis, which will be carried out by a statistician who is not involved in the trial. NUMBERS TO BE RANDOMISED (SAMPLE SIZE): Sample size could not be calculated, as there is no prior trial on KSK. This trial will be a pilot trial. Hence, we intend to recruit 60 participants in total using a 1:1 allocation ratio, with 30 participants randomised into each arm. TRIAL STATUS: Protocol version 2.0 dated 16(th) May 2020. Recruitment is completed. The trial started recruitment on the 25(th) May 2020. We anticipate study including data analysis will finish on November 2020. We also stated that protocol was submitted before the end of data collection TRIAL REGISTRATION: The study protocol was registered with clinical trial registry of India (CTRI) with CTRI/2020/05/025215 on 16 May 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol. The study protocol has been reported in accordance with the Standard Protocol Items: Recommendations for Clinical Interventional Trials (SPIRIT) guidelines (Additional file 2). SUPPLEMENTARY INFORMATION: Supplementary information accompanies this paper at 10.1186/s13063-020-04823-z.

A prospective, single centre, randomized open labelled comparative clinical study to evaluate the effectiveness of Siddha medicine, Kabasura kudineer and vitamin c-zinc supplementation in the management of asymptomatic COVID 19 patients.

Coronavirus disease 2019 (COVID-19) is a respiratory tract infection caused by a newly emergent coronavirus, SARS-CoV-2, that was first recognized in Wuhan, China, in December 2019. While most people with COVID-19 develop mild or uncomplicated illness, approximately 14% develop severe disease requiring hospitalization and oxygen support and 5% require admission to an intensive care unit. (1) In severe cases, COVID-19 can be complicated by acute respiratory disease syndrome (ARDS), sepsis and septic shock, multiorgan failure, including acute kidney injury and cardiac injury. The mortality rate of COVID-19 is still increasing in other countries than China now. At present, there is limited evidence from randomized clinical trials to support any vaccines or pharmacological treatments from conventional medicine for COVID-19. (2) According to Siddha system of medicine, the symptoms and signs of COVID-19 are identified as the aggravation of Iyam and which later associated with other Uyir thathukkal Vali and Azhal and expressed as Thontham (Mukkutram) leads to sanni.(3) Siddha medicine has played a major in controlling the mortality rate of chikungunya and dengue in Tamil Nadu by administration of Nilavembu Kudineer during 2015.(4) Siddha medicine has contributed in lowering health burden during public health emergency. Siddha Medicine has a good potential to combat COVID-19(5).

In this context, one of the classical formulations from Siddha system of medicine is Kabasura kudineer (KSK) consists of 15 herbals ingredients which individually has anti-viral activity (6) . Cucurbitacin B (-112.09), Cardiofoliolide (-111.5), Apigenin (-98.84) and Pyrethrin (-92.98) presented in the KSK were found to be effective in preventing novel corona virus binding and replication.(7) Determination of organoleptic characters, preliminary phytochemical analysis, physico-chemical analysis, TLC photo documentation and HPTLC fingerprint studies on KSK were analyzed. (8) Toxicological study on KSK showed that it is safe (9) . KSK also possess anti pyretic, anti-inflammatory and anti-bacterial effect. Vitamin c and zinc supplementation(CZ) is being prescribed for the COVID19 positive asymptomatic patients admitted in isolation ward. The role of CZ in the management of COVID19 is still not clear. Therefore, we propose to compare the effect of KSK and CZ in terms of negative conversion of SARS CoV-2 infection. to continue will be discontinued in the study.

The investigator will dispense the decoction and tablets ensuring the compliance of the drug administration. All the participants will be asked to take medicine in front of the 

As there is no prior work on this research question, so no assumptions for the sample size calculation could be made. The present study will serve as a pilot trial. We intend to study 60 patients, each 30 in two groups.

Simple randomization. All the eligible participants will be randomly assigned (in 1:1 ratio) in each arm to ensure balanced distribution between KSK and CZ arms. Randomization will be implemented by independent statistician who will not involve in data analysis. Equal numbers of cards with each arm assignment number randomly generated by computer will be placed in sequentially numbered envelops that will be opened on patient enrolling.

• No blinding.

Appropriate clinical sample will be collected by laboratory personnel/ health care worker trained in specimen collection in presence of a clinician by following all biosafety precautions and using personal protective equipment (PPEs), clinical samples will be sent to the designated laboratory (ICMR empanelled) by following standard triple packaging. 

Personal protective equipment (apron, hand gloves, face shield, N95 Masks etc.) will be used and all biosafety precautions will be followed so as to protect individuals and the environment. Proper labelling (name/age/gender/specimen ID) will be done on specimen container and other details of sender (name/address/phone number) on the outer container by mentioning "KSK_COVID_trial" All samples would be stored for future-related tests. Frequency and duration of monitoring: (i) Patients will be monitored daily until discharge from the hospital and followed up till 14 days;

Safety Assessment: (i) Elevation of ALT to more than five-fold upper normal limit; (ii) Anaphylaxis; and (iii) Adverse events and serious adverse events.

Laboratory outcomes: (i) Viral RNA loads and cycle threshold values in serial samples of nasopharyngeal and oropharyngeal swabs and blood, collected every week (to document anti-viral activity). (ii) Immunoglobulins values in serial samples of serum collected every week (to document immunomodulatory effect)

At the time of recruitment, we will collect socio-demographics, history of illness and clinical examination. At every visit we will do systematic clinical examination, determine adherence to interventions and assessment about any complaints and any adverse events. Both allopathic and Siddha physicians will perform clinical examination and collect relevant details according to their systems. The analysis plan on the primary and secondary outcome is described in the below table 

The purpose of the trial will be explained to all eligible SARS-CoV-2 confirmed patient. Informed consent will be obtained from all eligible participants willing to participate in the trial. Each participant will be informed that participation in the trial is voluntary and that s/he is free to withdraw, without justification, from the trial at any time without consequences and without affecting professional responsibilities. Informed consent will seek approval to collect blood samples and clinical data for the intended purpose of this trial.

This investigation poses minimal risk to participants, involving the collection of a small amount of blood. The direct benefit to the participant is the ability to detect SARS-CoV-2 viral load which would allow for appropriate monitoring and treatment. The primary benefit of the study is indirect in that data collected will help to find an intervention for the management of COVID-19.

Participant confidentiality will be maintained throughout the investigation. All subjects who participate in the investigation will be assigned a study identification number by the investigation team for the labelling of questionnaires and clinical specimens. The link of this identification number to individuals will be maintained by the investigation team and the CCRS and will not be disclosed elsewhere.

Study will be conducted according to AYUSH GCP guidelines.

All investigators don't have any conflict of interest with the study involved.

A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. The Lancet

COVID-19: An Update on the Epidemiological, Clinical, Preventive and Therapeutic Evidence and Guidelines of Integrative Chinese-Western Medicine for the Management of 2019 Novel Coronavirus Disease

Noi Nadal Noi Mudal Nadal. Chennai: Department of Indian Medicine and Homoeopathy

Antipyretic, anti-inflammatory and analgesic properties of nilavembu kudineer choornam: a classical preparation used in the treatment of chikungunya fever

Part II & III. Madras: Directorate of Indian Medicine and Homoeopathy

Kapa Sura Kudineer " -A Siddha Formulary Prediction for Swine Flu

Glycoprotein (2019-Ncov) Targeted Siddha Medicines Kabasura Kudineer and Thonthasura Kudineer -In silico Evidence for Corona Viral Drug

Antipyretic and Antibacterial Study of Kabasura Kudineer Choornam

Laboratory abnormalities in patients with COVID-2019 infection